GSK plc

UK-based global biopharma. Specialty medicines (HIV — dolutegravir franchise, respiratory — Nucala, Trelegy), vaccines (Shingrix for shingles, Arexvy for RSV), and general medicines. Spun off Haleon (consumer health) in 2022 to focus on innovative pharma and vaccines.

• monetization model: One-time product sales of prescription medicines/vaccines; licensing/royalties/collaboration revenue. (GSK 20-F FY2024, Business; Segment note. GSK files 20-F, not 10-K; no 10-Q. Source: sec.gov ; accession UNKNOWN.)
• revenue mix: FY2024 turnover £31,376m: Specialty Medicines £11,873m (~37.8%); General Medicines £10,121m (~32.3%); Vaccines £9,382m (~29.9%). (20-F FY2024, Segment note; source URL above.)
• who pays: Third-party payers/insurers, governments/tender bodies, hospitals/providers, wholesalers/distributors; patients pay cost-share. (20-F FY2024, Business/Risk Factors; source URL above.)
• margin_value_capture: Value accrues in patented Specialty Medicines and Vaccines; General Medicines faces generic/biosimilar erosion. Gross/operating margin not extracted here. (20-F FY2024, Business/Risk Factors; source URL above.)

• customer classes: Payers & Insurers, Health Systems & Providers, government/tender purchasers, wholesalers/distributors, patients. (20-F FY2024, Business/Customers; source URL above.)

GSK plc is a UK-incorporated global biopharmaceutical company. Its fiscal year ends 31 December, and because it is a foreign private issuer, its primary SEC filing is the annual Form 20-F, not a 10-K.

The single most important structural fact is that GSK completed the demerger of its Consumer Healthcare business into Haleon plc in July 2022. After the demerger, GSK is a pure-play biopharma company focused on vaccines, specialty medicines, and general medicines. This is broadly described in GSK’s 20-F business review; the precise demerger mechanics and retained Haleon equity should be confirmed against the 20-F because the ownership stake changed through subsequent sell-downs (needs primary source validation).

For fiscal 2023, GSK reported continuing operations turnover of approximately £30.3bn (needs primary source validation; [S1]). The reported segment mix was approximately:

GSK monetizes via:

• Direct product sales to governments, wholesalers, pharmacies, hospitals, and clinics.
• Long-term supply contracts for public immunization programs.
• Specialty pharmacy and payer reimbursement for HIV, oncology, and immunology drugs.
• Licensing/collaboration income where applicable, though the core driver is product revenue.

The payer is not always the end patient. For vaccines, the payer is often a government or institutional purchaser. For retail medicines, payers include insurers, PBMs, and public programs such as Medicare/Medicaid. This is the standard biopharma monetization model; the exact customer-concentration disclosures should be checked against the 20-F risk factors.

The most robust financial statement calculation available is gross margin.

Using the income statement from the GSK 20-F for 2023:

`

Gross margin = (Turnover − Cost of sales) / Turnover

= (£30,328m − £8,791m) / £30,328m

= £21,537m / £30,328m

≈ 71.0%

`

All three inputs are needs primary source validation and are taken from [S1]. The formula is verified; the line items must be re-checked against EDGAR.

A reported operating margin of approximately 22% can be derived if reported operating profit was approximately £6.7bn on £30.3bn turnover, but this reported operating figure is also needs primary source validation. The adjusted operating margin is often higher because GSK excludes amortization of intangibles, impairments, and restructuring; that adjusted figure should be obtained from the 20-F’s non-IFRS reconciliation, not from memory.

From GSK’s filing, the principal customer classes are:

• Government payers and procurement agencies for vaccines.
• Wholesalers for distribution to retail pharmacies.
• Hospitals and clinics for administered products.
• Managed care organizations / PBMs for reimbursed pharmaceuticals.

GSK’s 20-F does not necessarily name a single customer that accounts for more than 10% of revenue; this statement is needs primary source validation. If no customer exceeds 10%, that is itself a risk-mitigating fact because dependence on any one channel is limited.

I will not invent customer names. The available GSK 20-F material does not provide a verifiable list of top customers in this run. For a peer comparitor, Pfizer’s 10-K often names large US wholesalers such as McKesson, Cencora, and Cardinal Health in its revenue concentration disclosure; however, those names cannot be attributed to GSK without GSK’s own filing confirmation (needs primary source validation).

Therefore the safest filing-bound statement is:

GSK sells to wholesalers, hospitals, pharmacies, government entities, and other institutional buyers; no individual customer name is safely assertable from the current retrieval environment without marking it needs primary source validation.

GSK sells to categories, not always named end-customers. Based on the filing’s business review, the classes are:

• Government immunization programs — US CDC, UK NHS, Gavi/UNICEF for developing-country procurement, and national public health agencies.
• Wholesalers/distributors — for retail and hospital channels.
• Hospitals and clinics — for infused/injectable products and vaccines.
• Pharmacy benefit managers (PBMs) and specialty pharmacies — for HIV, respiratory, and specialty products.
• Retail pharmacies — for general medicines.

• Payer archetype: Prefers budget predictability, discounts, and outcomes data. Government vaccine contracts are highly price-sensitive.
• Prescriber archetype: Prefers efficacy, safety, guideline inclusion, and ease of use. For HIV, the switch market values reduced pill burden.
• Patient archetype: For chronic diseases, tolerability, dosing frequency, and cost-sharing are key.
• Institutional buyer archetype: Hospitals buy based on formulary status, price, and supply reliability.

I do not have an accessible, verified customer list from GSK’s 20-F in this run. The correct primary-source citation is the 20-F’s customer-concentration footnote, which must be retrieved and checked. The statement above about customer classes is structurally supported by [S1] but not by a named customer list.

Intervene layer (Context). Diversified big pharma toll-road customer. Shingrix and HIV franchise provide stable base; Arexvy RSV vaccine is a growth driver. Trades at low P/E relative to peers — value play within Intervene. ADR structure means some data artifacts in 13F ownership.

`

Global Arexvy revenue = £1,200m

USD equivalent = £1,200m × 1.25 = $1,500m

US revenue = $1,500m × 80% = $1,200m

Implied US doses = $1,200m / $220 = 5.45m doses

`

If the US mix falls to 70%, implied doses drop to 4.8m at $220. If global revenue is 20% lower, implied doses drop to 4.4m.

Nothing in this calculation is validated enough to drive conviction. It does show that small changes in price/mix drive large changes in implied volume. That matters because a competitive RSV market with Pfizer Abrysvo and potentially Moderna mRNA-1345 creates price/mix risk.

A second, more reliable calculation is gross margin, shown above:

`

Gross margin = (Turnover − Cost of sales) / Turnover ≈ 71%

`

The parameter table for that calculation is:

The gross margin is more meaningful for conviction because it is ledger-derived from the income statement, not market-price-assumed. Even so, it must be re-verified against the actual 20-F.